Quarterly results round-up: Boston still on road to recovery, Thermo Fisher and Zimmer solid
This article was originally published in Clinica
Executive Summary
Boston Scientific has continued to grow during its second fiscal quarter, helping to allay concerns sparked by CEO Ray Elliott's planned departure. He announced in May that he intends to retire at the end of the year, fuelling fears that the company's apparent turnaround could be short-lived, and triggering a drop in the company's share price (www.clinica.co.uk, 11 May 2011).